Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Completed · Phase 3
Conditions studied: Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
In brief
The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).
Key facts
- Study ID
- NCT02680756
- Run by
- Shield Therapeutics
- People needed
- 250
- Starts
- 2016-01-01
- Expected to finish
- 2019-01-01
- Last updated by the study team
- 2020-11-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Dothan, Alabama, United States
- Study site — Tucson, Arizona, United States
- Study site — Gainesville, Florida, United States
- Study site — Hollywood, Florida, United States
- Study site — Chevy Chase, Maryland, United States
- Study site — Saint Paul, Minnesota, United States
- Study site — St Louis, Missouri, United States
- Study site — Great Neck, New York, United States
- Study site — Lima, Ohio, United States
- Study site — Germantown, Tennessee, United States
- Study site — Nashville, Tennessee, United States
- Study site — Beaumont, Texas, United States
- Study site — Houston, Texas, United States
- Study site — San Antonio, Texas, United States
- Study site — Bountiful, Utah, United States
- Study site — Bellevue, Washington, United States
- Study site — Seattle, Washington, United States
- Study site — Ghent, Belgium
- Study site — Clichy, France
- Study site — Lille, France
- Study site — Lyon, France
- Study site — Saint-Etienne, France
- Study site — Salouël, France
- Study site — Vandœuvre-lès-Nancy, France
- Study site — Berlin, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.